Frontiers in Oncology (Oct 2021)

Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients

  • Wenwen Zhang,
  • Wenwen Zhang,
  • Wenwen Zhang,
  • Bingyang Hu,
  • Bingyang Hu,
  • Bingyang Hu,
  • Jun Han,
  • Jun Han,
  • Jun Han,
  • Zhanbo Wang,
  • Guangyu Ma,
  • Huiyi Ye,
  • Jing Yuan,
  • Junning Cao,
  • Ze Zhang,
  • Ze Zhang,
  • Ze Zhang,
  • Ze Zhang,
  • Jihang Shi,
  • Jihang Shi,
  • Jihang Shi,
  • Jihang Shi,
  • Mingyi Chen,
  • Mingyi Chen,
  • Mingyi Chen,
  • Xun Wang,
  • Yinzhe Xu,
  • Yinzhe Xu,
  • Yinzhe Xu,
  • Yanshuang Cheng,
  • Yanshuang Cheng,
  • Yanshuang Cheng,
  • Lantian Tian,
  • Hongguang Wang,
  • Shichun Lu,
  • Shichun Lu,
  • Shichun Lu

DOI
https://doi.org/10.3389/fonc.2021.747950
Journal volume & issue
Vol. 11

Abstract

Read online

Background and AimsImmunotherapy with PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) has been proven to be effective against advanced hepatocellular carcinoma (HCC). The aim of this study was to identify the feasibility and safety of subsequent salvage surgery after this combination therapy.Methods and PatientsA retrospective analysis was performed on patients with primary HCC with major vascular invasion between 2018 and 2019. All cases were treated with a combination of a PD-1 inhibitor and TKI agents and subsequent surgery.ResultsA total of 10 HCC cases with major vascular invasion met the successful conversion criteria after the combination therapy, and eight patients underwent subsequent salvage surgery after both radiology and 3D quantitative oncological assessment. Partial response (PR) was recorded in 7 of 10 patients and complete response (CR) in 3 of 10 patients before salvage surgery. Salvage surgery included right hepatectomy, left hepatectomy, and anatomic segmental hepatectomy. The mean intraoperative blood loss was 1,650 ml (50–3,000 ml). No complications beyond Clavien–Dindo level III or postoperative mortality were observed. The viable tumor cell rate of the PR cases (modified response evaluation criteria in solid tumors, mRECIST) varied from 1.5% to 100%, and only one patient had pathology-proven pathological complete response (pCR). The postoperative median follow-up time was 19.7 months (9.1–24.9 months). The 12-month recurrence-free survival rate of all cases who underwent salvage surgery was 75%.ConclusionSalvage surgery was effective and safe after conversion therapy with PD-1 inhibitors plus TKIs and may increase the long-term oncological benefit for patients with unresectable HCC.

Keywords